Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. on June 10, 2025. The report addresses a significant change in executive leadership within the company's finance department.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes.
Material Changes
- Departure of CFO: David Beers, Chief Financial Officer, was terminated without cause on June 10, 2025, pursuant to his employment agreement.
- Reason for Departure: The termination was explicitly stated as not related to the Company's financial or operating results, nor to any disagreements regarding financial or reporting practices.
- Interim Appointment: Joseph DosSantos, currently Senior Vice President of Finance, was appointed as Interim CFO effective June 10, 2025.
- Compensation: Mr. DosSantos will not receive additional compensation for his interim role. Mr. Beers is entitled to payments and benefits outlined in his agreement for a termination without cause, subject to a general release.
Guidance, Outlook, and Risks
The filing contains no updated financial guidance, outlook, or management commentary regarding future performance. The primary risk highlighted is the transition of financial leadership, though the company notes the departure was not due to operational or reporting concerns.
Investor Verification Checklist
- Verify the terms of the separation agreement and potential severance costs for the former CFO.
- Monitor the timeline for the search and appointment of a permanent Chief Financial Officer.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Confirm that the interim CFO has the necessary resources to maintain financial reporting standards during the transition.